Fase 0 workshop presso il XX Convegno EORTC-NSC-AACR, Geneva

S. Camporesi

Clinical studies of phase 0 are really necessary?

The question was raised by James Doroshow (National Cancer Institute, Bethesda, USA) at the Symposium EORT-NSC-AARC 20 molecular targets and Cancer Therapeutics (Geneva, 21-24 October 2008). Together with e. Leo (Beerse, Belgium), James Doroshow-since 2004 Director of the Division of cancer treatment and diagnosis NSC-was govern the workshop on clinical trials of phase 0. in his introduction to speakers, Doroshow raised six open questions, i.e. whether they are trials of phase 0 ethically acceptable, useful and feasible, if they accelerate the drug development process and save money, and if there is room for improvement.

Volume: 2 article number: 107 DOI: 10.3332/ecancer. 2008 107 received: 02/10/2008 published: 12/11/2008

To view this article in its entirety, you must first sign in or register.

View the original article here